# Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

> **NCT03905343** · PHASE3 · TERMINATED · sponsor: **Swiss Cancer Institute** · enrollment: 25 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ribociclib
- **OTHER:** Mono-chemotherapy
- **OTHER:** Endocrine-Therapy

## Key facts

- **NCT ID:** NCT03905343
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-25
- **Primary completion:** 2021-04-15
- **Final completion:** 2021-04-15
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Feasibility (low patient accrual and financial reasons)
- **Last updated:** 2021-06-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03905343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03905343, "Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03905343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*